NEXT GENERATION ANTIBODIES FOR CANCER DRUGS

Combining antibody therapies for cancer treatments to innovate Biomedical science in the 21st century

In the Chair:

Prof. Dr. Melvyn Little Chief Scientific Officer

AFFIMED THERAPEUTICS AG

In your eminent Speaker panel:

Professor Florian Wurm Founder and Chief Scientific Officer

EXCELLGENE SA

Dr. Wim Tiest, Director Project Office, Immunotherapeutics Business Unit

GLAXOSMITHKLINE BIOLOGICALS

Prof. Dr. Melvyn Little, Chief Scientific Officer

AFFIMED THERAPEUTICS AG

Professor Patrick A. Baeuerle, Senior Vice President and Chief Scientific Officer

MICROMET AG

Dr. Pablo Umaña, Chief Scientific Officer

GLYCART BIOTECHNOLOGY (ROCHE) 

Dr. Björn Frendéus, Senior Principal Scientist, Preclinical Research

BIOINVENT INTERNATIONAL

Prof. Dr. Christoph Renner, Department of Oncology

UNIVERSITY HOSPITAL, ZURICH

Event Summary:

In the Life Science industry, companies across the World are looking at targets to find new innovative treatment regimes in the field of oncology. Immunotherapy is one of the most promising areas within biomedical science to successfully identify new targets for cancer treatments in the human body. Antibodies hold most promise in the treatment of cancer due to its capabilities to activate the immune system.

By combining monoclonal antibody therapies with conventional cancer drugs, it is possible to reduce side effects. The immune system makes antibodies to attach to the antigens which destroy the cancer cells. Today, most pharmaceutical and biotechnology companies integrate antibody therapies and technologies for new drugs in order to personalise and provide better healthcare for cancer patients. By capitalising on antibodies, biopharmaceuticals are able to provide efficient cancer therapies with high margins to the market worldwide.

This international one day conference will provide your R & D organisation with a platform to harness the capabilities of antibodies to develop new and innovative cancer drugs. Our distinguished speaker panel will present the best strategies to successfully commercialise your scientific discoveries in a competitive business environment, the global Life Science industry.

This event will tackle key issues such as:

• Designing a strategy for next generation antibodies for cancer drugs to capture a prime position in an emerging marketplace
• Translational pharmacology: Exploring PD-Biomarkers and PK/PD-modelling to accelerate your drug development
• Examining current status and future trends in the antibody arena within life sciences
• Mastering an R & D strategy to combine immunotherapeutics with your oncology programme
• Developing a funding strategy to drive your antibodies for cancer drug  from concept to clinic
• Capitalising on personalised drugs to maximise your pipeline of cancer drugs and diagnostics
• Uncovering translational strategies for development of monoclonal antibodies
• Establishing partnerships in the Life Science industry to deliver combined antibody therapies for cancer treatments to the market

Target audience and Job titles:

Presidents, Chief Executive Officers, Chief Scientific Officers, Vice Presidents, Directors and Heads within:

• Cancer Immunotherapies
• Biologics Research
• Lead Discovery
• Oncology
• Research & Development
• Immunotherapy
• Translational Research and Pharmacology
• Immunobiology
• Biology
• Immunology & Antibody Engineering
• Discovery Research and Preclinical Development
• Cancer Research
• Oncology Biologics
• Antibody Discovery
• Technology
• Oncology – Immunotherapy
• Drug Discovery
• Scientists
• Venture Capitalists
• Consultants